Data Sheet (Cat.No.T15772)

TargetMol

Lodoxamide tromethamine

Chemical Properties



CAS No. : 63610-09-3

Formula: C19H28ClN5O12

Molecular Weight: 553.91

Storage: Store under nitrogen
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	Lodoxamide tromethamine is a mast cell stabilizer with anti-allergic properties and can be used in studies about the treatment of asthma and allergic conjunctivitis.
Targets(IC50)	Histamine Receptor
In vitro	In purified rat peritoneal mast cells, Lodoxamide tromethamine inhibits ionophore-induced 45Ca influx with associated histamine release[1]. Lodoxamide tromethamine significantly and dose-dependently inhibits the chemotactic response of eosinophils to fMLP and to IL-5. Lodoxamide tromethamine strongly inhibits the release of eosinophil peroxidase after IgA-dependent activation and inhibits the release of eosinophil cationic protein and eosinophil-derived neurotoxin to a lesser extent[4].
In vivo	In Ascaris-sensitized anesthetized rhesus monkeys, Lodoxamide tromethamine significantly inhibits the increased respiratory frequency and decreased tidal volume induced by antigen challenge[1]. The addition of Lodoxamide tromethamine to Euro-Collins or University of Wisconsin solution increases oxygenation, decreases microvascular permeability, and increases compliance thereby decreasing lung reperfusion injury[2].

Solubility Information

Solubility	DMSO: 15 mg/mL (27.08 mM),Sonication and heating are recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (3.61 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.8053 mL	9.0267 mL	18.0535 mL
5 mM	0.3611 mL	1.8053 mL	3.6107 mL
10 mM	0.1805 mL	0.9027 mL	1.8053 mL
50 mM	0.0361 mL	0.1805 mL	0.3611 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Watt GD, et al. Protective effect opf lodoxamide tromethamine on allergen inhalation challenge. J Allergy Clin Immunol. 1980 Oct;66(4):286-94.
Barr ML, et al. Addition of a mast cell stabilizing compound to organ preservation solutions decreases lung reperfusion injury. J Thorac Cardiovasc Surg. 1998 Mar;115(3):631-6; discussion 636-7.
Mann JS, et al. Inhaled lodoxamide tromethamine in the treatment of perennial asthma: a double-blind placebo-controlled study. J Allergy Clin Immunol. 1985 Jul;76(1):83-90.
Capron M,et al. Inhibitory effects of lodoxamide on eosinophil activation. Int Arch Allergy Immunol. 1998 Jun;116 (2):140-6.